BRUSSELS and INDIANAPOLIS, June 9,
2017 /PRNewswire/ -- More than 400 million people are living
with diabetes. In a further effort to help spread lessons learned
from clinical research to benefit people affected by this
condition, the International Diabetes Federation (IDF) and Eli
Lilly and Company (NYSE: LLY) have come together for the second
phase of the Bringing Research in Diabetes to Global Environments
and Systems programme (BRIDGES 2), reaffirming their commitment to
helping people with diabetes effectively manage their
condition.
BRIDGES 2 will build upon the work undertaken and the lessons
learned during the initial phase of the programme which operated
from 2007 to 2015. The programme will fund and replicate a
selection of projects from the initial phase, placing an emphasis
on the secondary prevention of diabetes and a strong involvement of
local public health authorities.
"Our goal is to translate evidence-based approaches from the
first round of BRIDGES to other contexts and countries to improve
the lives of people living with diabetes," said Robert A. Gabbay, Chair of the Steering Group of
BRIDGES 2.
This will enable the implementation of established
evidenced-based interventions and approaches to diabetes care.
BRIDGES 2 will further build on the achievements of the initial
phase that resulted in 41 diabetes prevention and treatment
projects supported in 36 countries.
"Diabetes is a growing epidemic, and we need to recognize and
address the diverse needs of people with diabetes," said
Robert Heine, Distinguished Lilly
Scholar. "The BRIDGES programme has been a valuable tool that has
led to important findings about the treatment of diabetes, and we
look forward to continuing this important work."
BRIDGES 2 will issue a request for grant proposals in
June 2017. All grant proposals will
be peer reviewed and prioritised by a cross-disciplinary external
review group under the coordination of IDF. A steering committee
composed with experts appointed by IDF and Lilly will determine the
selection of projects and types of grants that will be
available.
"IDF is proud of the achievements of the first phase of BRIDGES,
and we are delighted to have the opportunity to further replicate
the findings of the completed projects. We want to spread best
practices to those who need it most and help shape a better world
for the millions of people currently living with diabetes and the
many more at risk," said Shaukat
Sadikot, IDF President.
For more information about BRIDGES 2, please visit
www.idf.org/bridges or contact belma.malanda@idf.org.
NOTE TO EDITORS:
About the International Diabetes Federation
The
International Diabetes Federation (IDF, www.idf.org) is an umbrella
organisation of over 230 national diabetes associations in 165
countries and territories. It represents the interests of the
growing number of people with diabetes and those at risk.
The Federation has been leading the global diabetes community
since 1950. The Federation's activities aim to influence policy,
increase public awareness and encourage health improvement, promote
the exchange of high-quality information about diabetes, and
provide education for people with diabetes and their healthcare
providers. IDF is associated with the Department of Public
Information of the United Nations and is in official relations with
the World Health Organization (WHO) and the Pan American Health
Organization (PAHO). www.idf.org.
About Lilly
Lilly is a global healthcare leader that
unites caring with discovery to make life better for people around
the world. We were founded more than a century ago by a man
committed to creating high-quality medicines that meet real needs,
and today we remain true to that mission in all our work. Across
the globe, Lilly employees work to discover and bring life-changing
medicines to those who need them, improve the understanding and
management of disease and give back to communities through
philanthropy and volunteerism. To learn more about Lilly, please
visit us at www.lilly.com and
www.lilly.com/newsroom/social-channels.
ADDENDUM:
BRIDGES 2 - KEY DATES
Pre-selection phase
- February-March 2017: BRIDGES 2
Steering Group members to discuss the selection of projects from
the initial BRIDGES programme that will be replicated.
-
- A key requirement used in the selection of these projects is
that they must focus on secondary prevention.
- The projects will be assessed on the following criteria: i)
Evidenced based outcomes, ii) Efficacious process, iii) Scalability
and iv) Sustainability.
- Geographical data from the World Bank will be used to exclude
high income countries.
- Excluded from consideration will be proposals that involve the
testing of pharmaceuticals, disease mechanism studies or any other
projects that may be construed as product development or marketing
or sales interventions.
- June 2017: Grant announcement at
the 77th ADA Scientific Sessions, San
Diego, California, US which will be determined by a steering
committee appointed by IDF. This period will also mark the opening
of the application process
-
- August 11, 2017: Final submission
date for applications
Award Phase
- September 2017: An announcement
of selected projects and grant recipients will be made at the 53rd
EASD Annual Meeting to be held in Lisbon this year.
- October 2017: Contract signing
between BRIDGES 2 Steering Group and selected applicants
Implementation and Evaluation Phases
- December 2017- February 2018: Start of project
implementation
Workshops will be held to aid in the implementation process. These
workshops will include sessions on study designs, recruitment
methods and analysis techniques.
- 2018-2019: A two year intervention leading up to a final
reporting of outcomes at the IDF Congress 2019 in Busan, South Korea
-
- Projects will be reviewed in terms of scalability, possibility
of global replication and significance of findings
- Successful projects that meet the specified evaluation criteria
and are perceived to have significant regional and/or global impact
will be considered for dissemination
- Key findings will be distributed in the form of oral
presentations at major diabetes meetings (including the IDF
Congress 2019) and through scientific publications
C-LLY
Refer to: Lorenzo Piemonte; media@idf.org; +32 2543
1624 (IDF)
Greg Kueterman;
kueterman_gregory_andrew@lilly.com; (317) 432-5195 (Lilly)
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/idf-in-partnership-with-lilly-announces-second-phase-of-bridges-programme-funding-for-translational-research-in-diabetes-with-focus-on-secondary-prevention-300471410.html
SOURCE Eli Lilly and Company